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reckoner. Antimicrobial stewardship is the need of the hour and
every hospital irrespective of its size, scale or resource status must
adopt AMS. I believe that the model of AMS discussed here offers
a viable solution to implement AMS in a resource limited setting.
The clinical and cost outcome measures in the coming years will
further establish the full utility of this model in the hospital setup.
http://dx.doi.org/10.1016/j.ijid.2014.03.581
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The World Health Assembly’s adoption of the Decade of Vac-
cines and the Global Vaccine Action Plan (GVAP) provides us with a
global mandate to accelerate the introduction of new vaccines into
developing countries, with an emphasis on previously neglected
diseases. The remarkable success in the development and intro-
duction of human papilloma virus vaccines demonstrates that this
can be done, despite the stigma associated with sexually transmit-
ted pathogens. In Australia and the United States there is already
evidence of the impact of the HPV vaccine in reducing the spread
of oncogenic HPV types, as well as signiﬁcant clinical impact on
genital warts. There is now amajor push to introduce HPV vaccines
into theAfrican region supportedby theGlobalAllianceonVaccines
and Immunization (GAVI)whichhasnegotiatedmassive reductions
in vaccine prices. Pilot studies have been successfully undertaken
in Uganda and Tanzania, and Rwanda has successfully introduced
the vaccine with South Africa committed to do this in 2014. This
talk will address the many questions that African countries need to
considerwhen introducingHPV vaccines: age group, girls and boys,
programmatic decisions including where to immunize and dosing
schedules, and will consider what the potential long term impact
of these vaccines could be on the epidemiology of HPV within the
region.
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Gonorrhoea remains a common sexually transmitted infection
and enhances both the transmission and acquisition of HIV in high
prevalence settings. The capacity to treat, and thereby control,
gonorrhoea diminishes as antimicrobial resistance (AMR) wors-
ens. Enhanced efforts are urgently required to reduce the global
burden of gonorrhoea and simultaneous sustained AMR contain-
ment measures are also needed to limit antimicrobial misuse. Both
approaches are critical for reducing the rate of emergence and
spread of AMR determinants to Neisseria gonorrhoeae. Expanded
surveillance of gonococcal AMR, urgently needed for provision
of valid data worldwide, has been initiated by the World Health
Organization and various national public health laboratories. These
surveillance programmes may identify the emergence and trans-
mission of novel AMR-associated N. gonorrhoeae strains. They
also provide the evidence base to update STI management and
treatment guidelines. In the absence of AMR surveillance, many
countries continue to use old antimicrobial agents without any
idea as to current drug efﬁcacy. Critically, within the context
of gonorrhoea control, decreased susceptible N. gonorrhoeae iso-
lates displaying elevated minimum inhibitory concentrations to
the extended spectrum cephalosporins are now being identiﬁed
in many countries. However, the imprecise nature of laboratory
criteria for detecting these gonococci means that the distribution
and prevalence of these strains, as well as multi drug-resistant
(MDR)andextensivelydrug-resistant (XDR)N. gonorrhoeae, remain
uncertain. The availability and affordability of high quality efﬁca-
cious antimicrobial agents in all settings and countries is essential.
Achieving this goal will be difﬁcult but failure to do so will
only accelerate the spread of existing MDR-NG and the further
emergence of XDR-NG. Finally, given the challenge of achieving
sustained sexual behaviour change, research initiatives to develop
an effective vaccine for gonorrhoea are crucial in an era of reduced
research funding and must be prioritized.
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